Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...
AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback